Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 279Gynecologic 10Other 4Tumor-Agnostic 3Thoracic 2Endocrine 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Endocrine Neoplasia Type 1 2Sexual Dysfunction, Physiological 1Seizures 1Neoplasm Metastasis 1Hypogonadism 1Erectile Dysfunction 1Epilepsy 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anastrozole × Endocrine × Clear all
NCT02753686 2023-02-15

Treat ER+ight

Novartis

Completed
440 enrolled
Endocrine

Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT00179517 2019-07-17

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Beth Israel Deaconess Medical Center

Phase 2 Completed
40 enrolled 13 charts
EndocrineOther

Epilepsy, Hypogonadism, Erectile Dysfunction, Seizures, Sexual Dysfunction, Physiological, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡